TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06716138: A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ANS03 as a Single Agent in Participants With Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alterat

Sponsor: Avistone Biotechnology Co., Ltd. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 96 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$9,519,048

Rescue Site Savings

+$6,283,200

Unlock Full NCT06716138 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06716138 Rescue Dossier →